Home > Insider Trading > Filing (0001209191-17-037286)

Filing Details

Accession Number:: 0001209191-17-037286
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-06-02 16:37:57
Reporting Period:: 2017-06-01

Filing Date:: 2017-06-02
Accepted Time:: 2017-06-02 16:37:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
893949	Mednax Inc.	MD	Services-Hospitals (8060)	263667538

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1218834	M Joseph Calabro	1301 Concord Terrace Sunrise FL 33323	President And Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-06-01	67,398	$0.00	296,379	No	4	A	Direct
Common Stock	Disposition	2017-06-01	23,327	$55.00	262,784	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 16,849 additional shares based on the achievement of certain performance-based criteria for the period from April 1, 2017 through March 31, 2018. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three equal installments on June 1, 2018, June 1, 2019 and June 1, 2020.
Sales made pursuant to Reporting Person's 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in sixty-four (64) separate transactions with prices ranging from $54.13 to $55.40 for an average weighted sales price of $54.9978. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Reflects a reduction of 10,268 in previously reported target restricted shares that were granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with achievement of specified performance-based criteria below target for the performance period from April 1, 2016 through March 31, 2017. The decrease in restricted shares impacts the installments vesting on June 1, 2017, June 1, 2018 and June 1, 2019. The vesting of such shares remains subject to continued employment.